Login
$CGON
$84.48 -$0.30 (0.35%) After hours

$CGON SEC Filings

Filed On Filing
16 Nov 2026 8-K: Regulation FD Disclosure; Other Events

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

06 Nov 2026 10-Q
06 Nov 2026 8-K: Results of Operations and Financial Condition

DALLAS, Texas, November 6, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the third quarter ended September 30, 2026, and provided business updates.

19 Oct 2026 Form 4: Kalofonos Isabel, Chief Commercial Officer

Granted 92,000 Employee Stock Option (right to buy)

19 Oct 2026 Form 4: Post Leonard E, Director

Received 1,000 shares by exercise or conversion ($600) · Sold 1,000 shares ($62.1K)

19 Oct 2026 Form 3: Kalofonos Isabel, Chief Commercial Officer

No securities owned

15 Oct 2026 144
21 Sep 2026 144
17 Sep 2026 144
17 Sep 2026 Form 4: Post Leonard E, Director

Received 1,000 shares by exercise or conversion ($600) · Sold 1,000 shares ($73K)

11 Sep 2026 144
02 Sep 2026 144
31 Aug 2026 144
27 Aug 2026 144
25 Aug 2026 144
24 Aug 2026 144
19 Aug 2026 144
18 Aug 2026 Form 4: Post Leonard E, Director

Received 1,000 shares by exercise or conversion ($600) · Sold 1,000 shares ($74.5K)

17 Aug 2026 144
14 Aug 2026 144

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support